Hepatoprotective agent, has a choleretic effect. Reduces synthesis of cholesterol in the liver, its absorption in the intestine and bile concentration raises the solubility of cholesterol in the biliary system and stimulates the production of bile. Reduces lithogenic bile, increases in its content of bile acids; causes increased gastric and pancreatic secretion, increases lipase activity exerts hypoglycemic action. It is a partial or complete dissolution of cholesterol stones in enteral application, reduces the saturation of bile with cholesterol, which contributes to the mobilization of cholesterol from gallstones. Has immunomodulatory effects, influences the immunological reaction in the liver: decrease the expression of certain antigens on the membrane of hepatocytes, affects the amount of cypionate, interleukin-2, reduces the number of eosinophils.
Dissolution of cholesterol gallstones, biliary reflux gastritis, primary biliary cirrhosis in the absence of signs of decompensation (symptomatic treatment).
Rentgenopolozhitelnye (high calcium content) gallstones; non-functioning gall bladder; acute inflammatory diseases of the gallbladder, bile ducts and intestines;cirrhosis of the liver in the stage of decompensation; expressed by the human kidney, liver, pancreas; hypersensitivity to the drug. Ursodeoxycholic acid has no age restrictions in the application, but for children up to 3 years, it is recommended to apply in Ursofalk suspension, as you may experience difficulty in swallowing the capsules.
Pregnancy and lactation
The drug is contraindicated during pregnancy and lactation.
Children and adults weighing less than 34 kg is recommended to use in Ursofalk suspension.
Diarrhoea, nausea, pain in the epigastric and right upper quadrant, the calcination gallstones, increased activity of “liver” enzymes, allergic reactions.
In the treatment of primary biliary cirrhosis cypionate may be a transient decompensation of cirrhosis, which disappears after discontinuation of the drug.
No cases of overdose have been identified. In case of overdose symptomatic treatment.
INTERACTION WITH OTHER DRUGS
Cholestyramine, colestipol, antacids containing aluminum hydroxide or smectite (aluminum oxide), reduce the absorption of ursodeoxycholic acid in the intestine and thereby reduce its absorption and effectiveness. If the use of preparations containing at least one of these substances, yet necessary, they should be taken at least 2 hours before taking Ursofalk.
Ursodeoxycholic acid can enhance the absorption of cyclosporin from the gut. Therefore, in patients receiving cyclosporin, the physician must check the blood concentration of cyclosporine and cyclosporine dose adjusted if necessary.
In some cases, Ursofalk can reduce the absorption of ciprofloxacin. Lipid-lowering agents (especially clofibrate), estrogens, progestins or neomycin increased saturation of bile with cholesterol and may reduce the ability to dissolve cholesterol gallstones.
If cholelithiasis monitoring the effectiveness of treatment is carried out every 6 months by means of X-ray and ultrasound of biliary tract in order to prevent recurrence of cholelithiasis. In cypionate cholestatic liver diseases periodically to determine the activity of transaminases, alkaline phosphatase and gamma glutamyl serum.